San Francisco, 07, Oncology Based In-vivo CRO Market Analysis By
Indication (Blood cancer, Solid tumor), By Model (Syngeneic model, Patient
Derived Xenograft (PDX), Xenograft), By Region, And Segment Forecasts, 2018 -
2025
The global oncology based in-vivo CROmarket is expected to reach USD
1.5 billion by 2025, according to a new report by Grand View Research, Inc. The
use of Contract Research Organization (CRO) oncology services helps the
manufacturers/sponsors to provide complete attention on the production capacity
and at enhancing their in-house processes.
Furthermore, the pressure from the increasing competition
due to patent expirations, rapid growth of generics, and introduction of
biosimilar equivalents are propelling the pharmaceutical companies to take the
aid of such organizations. Hence, it can be predicted that the oncology based in-vivo CRO market may witness lucrative growth
over the forecast period.
Another factor propelling
growth is the increasing incidence of cancer, and high failure rate of existing
treatment options. According to statistics published by the World Health
Organization (WHO), approximately 8.2 million deaths are recorded each year
from cancer, which accounts for 13.0% deaths worldwide.
Access Full Research
Report On Oncology Based In-vivo CRO Market Analysis:
Further key findings from the study suggest:
·
Based on indication, solid
tumors are expected to dominate the market as of 2016. Furthermore, it is
anticipated to grow at the fastest CAGR owing to the factors such as growing
incidence rate, augmenting research for tumors in organs such as breast, and liver,
and technological advancement offered by key industry players.
·
Solid tumors are analyzed by
means of models such as xenograft, Patient Derived Xenografts (PDX), and
syngeneic. The PDX models are expected to witness lucrative growth over the
forecast period and capture over 40.0% of the market share by 2025.
·
Geographic expansion into Asia
Pacific countries by well-established players is anticipated to promote the
fastest growth for the region. India is one the most lucrative country owing to
presence of service tax exemption and venture capital based funding for CROs.
·
Few of the industry players for
the oncology based in-vivo CRO
market are The Jackson Laboratory, Covance, Taconic Biosciences, Charles River
Laboratory, EVOTEC, Wuxi AppTec, and ICON Plc.
·
A common trend observed is the
rising partnerships among CROs to offer bundle packages of services to
sponsors. For instance, In May 2017, CRL International, Inc. announced their
partnership with OcellO, established in Netherlands. According to this partnership,
CRL would be utilizing the latter’s PDX model capabilities in order to expand
their oncology based drug discovery service portfolio.
Browse More Reports Of This
Category By Grand View Research At: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the global oncology
based in-vivo CRO market on the basis of indication,
and region:
Global Oncology Product Outlook
(Revenue, USD Million, 2014 - 2025)
·
Blood cancer
·
Solid tumors
o
Syngeneic model
o
Patient Derived Xenograft (PDX)
o
Xenograft
·
Others
Oncology in-vivo CRO Regional Outlook (Revenue, USD Million, 2014 -
2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
UK
o
Germany
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
o
Argentina
·
Middle East and Africa (MEA)
o
South Africa
o
Saudi Arabia
Access Full Press Release of this Report:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San
Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For more information: www.grandviewresearch.com/
No comments:
Post a Comment